for significant small molecule drugs, there is commonly a cohort of generic firms ready at expiry. There is usually little barrier to entry beyond the patent or regulatory exclusivities. Prices are typically crushed after the 6 months. Biologics (antibodies/ vaccines) are a different story because of the complexity of their manufacturing and characterization.